1. Home
  2. JXJT vs BCDA Comparison

JXJT vs BCDA Comparison

Compare JXJT & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JXJT
  • BCDA
  • Stock Information
  • Founded
  • JXJT 2012
  • BCDA N/A
  • Country
  • JXJT China
  • BCDA United States
  • Employees
  • JXJT N/A
  • BCDA N/A
  • Industry
  • JXJT Apparel
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • JXJT Consumer Staples
  • BCDA Health Care
  • Exchange
  • JXJT Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • JXJT 8.1M
  • BCDA 9.4M
  • IPO Year
  • JXJT 2012
  • BCDA N/A
  • Fundamental
  • Price
  • JXJT $1.23
  • BCDA $3.25
  • Analyst Decision
  • JXJT
  • BCDA Strong Buy
  • Analyst Count
  • JXJT 0
  • BCDA 1
  • Target Price
  • JXJT N/A
  • BCDA $60.00
  • AVG Volume (30 Days)
  • JXJT 647.3K
  • BCDA 57.6K
  • Earning Date
  • JXJT 08-14-2024
  • BCDA 08-07-2024
  • Dividend Yield
  • JXJT N/A
  • BCDA N/A
  • EPS Growth
  • JXJT N/A
  • BCDA N/A
  • EPS
  • JXJT 0.48
  • BCDA N/A
  • Revenue
  • JXJT $31,840,588.00
  • BCDA $468,000.00
  • Revenue This Year
  • JXJT N/A
  • BCDA N/A
  • Revenue Next Year
  • JXJT N/A
  • BCDA $436.41
  • P/E Ratio
  • JXJT $2.56
  • BCDA N/A
  • Revenue Growth
  • JXJT N/A
  • BCDA N/A
  • 52 Week Low
  • JXJT $1.04
  • BCDA $2.62
  • 52 Week High
  • JXJT $8.51
  • BCDA $39.60
  • Technical
  • Relative Strength Index (RSI)
  • JXJT 48.12
  • BCDA 42.62
  • Support Level
  • JXJT $1.14
  • BCDA $2.62
  • Resistance Level
  • JXJT $1.61
  • BCDA $3.38
  • Average True Range (ATR)
  • JXJT 0.20
  • BCDA 0.30
  • MACD
  • JXJT 0.01
  • BCDA 0.11
  • Stochastic Oscillator
  • JXJT 16.35
  • BCDA 82.88

About JXJT JX Luxventure Limited

JX Luxventure Ltd is engaged in the business of menswear, cross-border merchandise, airfare, and tourism. The company operates in three segments Tourism products, Technology and Cross- board merchandise. The majority of the group revenue is generated from the Tourism products.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: